News & Publications
Press Releases
March 31, 2025
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board >> READ MORE
January 2, 2025
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics >> READ MORE
October 23, 2024
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium >> READ MORE
October 15, 2024
Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor >> READ MORE
September 25, 2024
Atavistik Bio Appoints Oncology Clinical Development Leader Mohammad Hirmand, M.D. to Board of Directors >> READ MORE
August 12, 2024
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer >> READ MORE
December 19, 2023
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics >> READ MORE
July 17, 2023
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer >> READ MORE
March 13, 2023
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform >> READ MORE
January 10, 2023
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics >> READ MORE
September 20, 2022
Atavistik Bio Announces Formation of Scientific Advisory Board >> READ MORE
August 24, 2021
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer >> READ MORE
Publications
August 30, 2024
Recent AI/ML applications assist in the discovery of allosteric modulators as discussed by Atavistik Bio in ACS Medicinal Chemistry Letters
>> Read Article
March 28, 2023
Examples of Multicomponent reactions (MCR) show impact towards the discovery of clinical compounds and expansion of topologically rich molecular chemotypes as described by Atavistik Bio in ACSMedicinal Chemistry Letters
>> Read Article
March 9, 2023
Atavistik Bio’s foundational technology to systematically identify and characterize the complex network of protein-metabolite interactions and their regulatory significance described in recent Science publication.
>> Read Article
Perspectives
The Search to Unlock Protein-Metabolite Interactions
An interview with Jared Rutter, Ph.D. and Kevin Hicks, Ph.D. About Atavistik Bio’s Foundational Technology and the Inspiration
>> Read More